Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 14, 2013, Pages 1875-1884

  Gualtierotti, Roberta ^a   Zoppi, Annalisa ^b   Mugellini, Amedeo ^b   Derosa, Giuseppe ^b   D'angelo, Angela ^b   Fogari, Roberto ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Acetaminophen; Aliskiren; Naproxen; Osteoarthritis; Ramipril; Valsartan

Indexed keywords

ALISKIREN; NAPROXEN; PARACETAMOL; RAMIPRIL; VALSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; ELEVATED BLOOD PRESSURE; FEMALE; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ACETAMINOPHEN; ADULT; AGED; AMIDES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NAPROXEN; RAMIPRIL; TETRAZOLES; VALINE;

EID: 84884218634     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.816286     Document Type: Article

References (44)

1. Magagna A, Abdel-Haq B, Favilla S, et al. Indomethacin raises blood pressure in untreated essential hypertensives: A double-blind randomly allocated study vs placebo. J Hypertens 1991;9(Suppl):S42-3
2. Pope JE, Andersen JJ, Felson DT. A meta-analysis of the effects of non steroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477-84
3. Johnson A, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressurëA meta-analysis. Ann Intern Med 1994;121:289-300
4. Salvetti A, Abdel-Haq B, Magagna A, Pedrinelli R. Indomethacin reduces the antihypertensive effect of enalapril. Clin Exp Hypertens A 1987;9:559-67
5. Morgan TO, Anderson A, Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens 2000;13:1161-7
6. Conlin PR, Moore TJ, Swartz SL, et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension 2000;36:461-5
7. Fogari R, Zoppi A, Carretta R, et al. on behalf of the Italian Collaborative Study Group. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: A multicentre study. J Hypertens 2002;20:1007-14
8. Palmer R, Weiss R, Zusman RM, et al. Effects of nabumetone, celecoxib and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. Am J Hypertens 2003;16:135-9
9. Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987;32:1-12
10. Oates JA, Fitzgerald GA, Branch RA, et al. Clinical implications of prostaglandin and thromboxane A2 formation. N Engl J Med 1988;319:689-98
11. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials. Lancet 2013. [Epub ahead of print
12. Hermann M. Cardiovascular risk associated with non steroidal anti-inflammatory drugs. Curr Rheumatol Rep 2009;11:31-5
13. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal antiinflammatory drugs increase the risk of atherothrombosis̈Meta-analysis of randomised trials. BMJ 2006;332:1302-8
14. Antman EM, Bennett JS, Daugherty A, et al. Use of non steroidal anti-inflammatory drugs: An update for clinicians: A scientific statement from the American Heart Association. Circulation 2007;115:1634-42
15. Sudano I, Flammer AJ, Périat D, et al. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation 2010;122:1789-96
16. Forman JP, Rimm EB, Curhan GC. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007;167:394-9
17. Forman JP, Stamfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005;46:500-7
18. Chalmer JP, West MJ, Wing LM, et al. Effects of indomethacin, sulindac, naproxen, aspirin and paracetamol in treated hypertensive patients. Clin Exp Hypertens 1984;6:1077-93
19. Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the efficacy of antihypertensive drugs: A randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med 1987;107:628-35
20. Pavlicevic I, Kuzmanic M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and NSAIDs in primary care: A controlled Trial. Can J Clin Pharmacol 2008;15:e372-82
21. Mac Kenzie IS, MacDonald TM. Treatment of osteoarthritis in hypertensive patients. Expert Opin Pharmacother 2010;11:393-403
22. Senn S. Cross-over trials in clinical research. 1st edition. John Wiley; New York: 1993
23. Groppelli A, Omboni S, Ravogli A, et al. Validation of the Spacelabs 90202 and 90207 devices for ambulatory blood pressure monitoring by comparison with intra-arterial resting and ambulatory measurements. J Hypertens 1991;9(Suppl3):S334-5
24. Parati G, Bosi S, Castellano M, et al. Guidelines for 24-hour non invasive ambulatory blood pressure monitoring: Report from a working group of the Italian Society of Hypertension. High Blood Press 1995;4:168-74
25. Morsing P, Adler G, Brandt-Eliasson U, et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 1999;33(6):1406-13
26. Quilley J, Duchin KL, Hudes EM, McGiff JC. The antihypertensive effect of captopril in essential hypertension: Relationship to prostaglandins and the kallikrein-kinin system. J Hypertens 1987;5:121-8
27. Zusman RM. Effects of converting enzyme inhibition on the reninangiotensin- aldosterone, bradykinin and arachidonic acid-prostaglandin systems: Correlation of chemical structure and biologic activity. Am J Kidney Dis 1987;10(Suppl1):13-23
28. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997;100:264-9
29. Volpe M, De Paolis P. Angiotensin II AT2 subtype receptors: An emerging target for cardiovascular therapy. Ital Heart J 2000;1:96-103
30. Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 1995;26:164-70
31. Tsutsumi Y, Matsubara H, Masaki H, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999;104:925-35
32. Jensen C, Herold P, Brunner HR. Aliskiren: The first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008;7:399-410
33. Mattammal MB, Zenser TV, Brown WW, et al. Mechanism of inhibition of renal prostaglandin by acetaminophen. J Pharmacol Exp Ther 1979;210:405-9
34. Graham GC, Scott KF. Mechanism of action of paracetamol. Am J Ther 2005;12:46-55
35. Flower RJ, Vane Jr.. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 1972;240:410-11
36. Aronoff DM, Oates JA, Boutaud O. New insights into the mechanism of action of acetaminophen: Its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin Pharmacol Ther 2006;79(1):9-19
37. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3,a ciclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure and expression. Proc Natl Acad Sci USA 2002;99:13926-31
38. Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxigenase-2 inhibitor in man. FASEB J 2008;22:383-90
39. Bertolini A, Ferrari A, Ottani A, et al. Paracetamol: New vistas of an old drug. CNS Drug Rev 2006;12:250-75
40. Hinz B, Brune K. Paracetamol and cyclooxygenase inhibition: Is there a cause for concern̈Ann Rheum Dis 2012;71(1):20-5
41. Cook NR, Cohen J, Hebert PR, et al. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995;155:701-9
42. Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease and death: The NHANES-I epidemiologic follow-up study. Am Heart J 1993;125:1148-54
43. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens 1997;15:3-17
44. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64(4):465-74